Allogene is developing allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapy to find the next immunologic breakthrough in cancer. That’s how we’re leading today, creating tomorrow.
WE DON’T JUST SEE THE FUTURE.
WE KNOW HOW TO GET THERE.
Allogene is working to overcome the limitations of autologous CAR T immunotherapy by developing AlloCAR T™ therapies. The goal of our allogeneic platform is simple: combine gene-editing technology with cutting-edge cell-therapy manufacturing to deliver the clinical benefits of cell therapy. We start with T cells from healthy donors to allow for the creation of off-the-shelf inventory for the potential to treat all eligible patients faster, more reliably, and at greater scale.
OUR VIRTUAL EXHIBIT
This is a virtual environment with interactive information on the latest advances in AlloCAR T™ therapy as well as our pipeline, clinical trials, and online resources.
